Compare GSK plc (GSK) vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? GSK plc trades at $50.38 (market cap $102.60B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $17.96. The key difference: GSK plc pays a 3.57% dividend while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF pays none, and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is trading nearer its 52-week high, GSK plc nearer its low. Which is the better fit depends on your goals.
| GSK | PDBC | |
|---|---|---|
Market Cap | $102.60B | — |
Sector | Health | — |
52-Week High | $61.18 | $18.91 |
52-Week Low | $38.22 | $12.90 |
Enterprise Value | $123.04B | — |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
PDBC trades at $17.94, up 0.62% with strong bullish technical signals from moving averages and a neutral RSI. The ETF has gained institutional interest with recent large purchases by Geneos Wealth Management and Advisortrust Partners. Commodity markets face geopolitical tensions that could drive volatility, while PDBC's structure avoids K-1 tax complexities but carries roll costs. Recent performance shows 37% returns since March 2024, outpacing the S&P 500 by 10 percentage points.
Outlook remains cautiously optimistic given commodity strength and defensive rotation trends, though momentum has recently weakened. Key risks include Middle East tensions affecting oil supplies, interest rate uncertainty, and inherent commodity volatility. The ETF offers diversified commodity exposure without K-1 tax forms, making it attractive for inflation hedging despite structural costs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →
